US 2013/0158264 A1 · Polymorphs of OSI-906

Abstract

Polymorphic forms of the tyrosine kinase inhibitor OSI-906, preparation, pharmaceutical compositions, and uses thereof. The invention includes methods of treating diseases such as cancer, including cancer mediated at least in part by IGF-1 R and/or IR, with the polymorphs and compositions. This Abstract is not limiting of the invention.

Claims20

Dependent claims

Crystalline polymorph Form A of OSI-906.

Dependencies are inferred from the claim text.

Facts

Application

13/805,402Filed 23 Jun 2011

Priority

23 Jun 2010

Published

20 Jun 2013

Term ends

Not estimatedThe source records don’t support an estimate.

Classification7 codes

C07D 487/04
In which the condensed system contains two hetero rings: ortho-condensed systems
A61K 31/4985
Having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines: pyrazines or piperazines…
A61P 35/00
Antineoplastic agents
A61P 43/00
Drugs for specific purposes, not provided for in groups a61p1/00-a61p41/00

Abstract

Claims20

Dependent claims

Crystalline polymorph Form A of OSI-906.

Dependencies are inferred from the claim text.

Polymorphs of OSI-906

Life of this patent

Abstract

Claims20

Polymorphs of OSI-906

Life of this patent

Abstract

Claims20